Pfizer Inc. PFE shares are trading lower by about half a percent on Monday as investors digest a leadership transition in the finance seat. Here’s what investors need to know. Pfizer stock is taking a ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Many income investors probably have mixed emotions about stocks with ultra-high dividend yields. On one hand, they love the tremendous income these stocks provide. On the other hand, they might worry ...

Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.

There are actually two factors to consider in the current drawdown. The first is the massive stock price spike that occurred during the coronavirus pandemic. Pfizer was one of a small number of ...

Could this be the secret to Pfizer's rebound strategy?

Pfizer (NYSE: PFE) announced on Tuesday that it had signed an agreement with the White House that will help Americans pay lower prices for prescription drugs and bolster U.S. leadership in ...

Pfizer Inc. secures Metsera, Inc. acquisition, outbidding Novo Nordisk, with a deal valued up to $86.25 per share including milestone CVRs. The board favored PFE's offer due to higher certainty of ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings supporting a compelling value thesis. BRAFTOVI's Phase 3 success and PADCEV + ...